Year: 2023
Type: review
Abstract: TDP-43 is an RNA-binding protein with a crucial nuclear role in splicing, and mislocalises from the nucleus to the cytoplasm in a range of neurodegenerative disorders. TDP-43 proteinopathy spans a spectrum of incurable, heterogeneous, and increasingly prevalent neurodegenerative diseases, including the amyotrophic lateral sclerosis and frontotemporal dementia disease spectrum and a significant fraction of Alzheimer's disease. There are currently no directed disease-modifying therapies for TDP-43 proteinopathies, and no way to distinguish who is affected before death. It is now clear that TDP-43 proteinopathy leads to a number of molecular changes, including the de-repression and inclusion of cryptic exons. Importantly, some of these cryptic exons lead to the loss of crucial neuronal proteins and have been shown to be key pathogenic players in disease pathogenesis (e.g., STMN2), as well as being able to modify disease progression (e.g., UNC13A). Thus, these aberrant splicing events make promising novel therapeutic targets to restore functional gene expression. Moreover, presence of these cryptic exons is highly specific to patients and areas of the brain affected by TDP-43 proteinopathy, offering the potential to develop biomarkers for early detection and stratification of patients. In summary, the discovery of cryptic exons gives hope for novel diagnostics and therapeutics on the horizon for TDP-43 proteinopathies.
Source: Molecular Neurodegeneration
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,990
Funders: Wellcome Trust, National Institute for Health and Care Research, University College London Hospitals NHS Foundation Trust, National Institutes of Health, Medical Research Council, National Institute of Neurological Disorders and Stroke, Robert Packard Center for ALS Research, Johns Hopkins University
Awards: UCL Wellcome Trust PhD Programme for Clinicians, The impact of TDP-43 on translation and the response to axonal damage in amyotrophic lateral sclerosis, Investigating deficits of axonal RNA metabolism and axonal signalling in amyotrophic lateral sclerosis, Discovery of novel TDP-43 splicing targets: the Achilles heel for FTD and towards sensitive biomarkers and therapeutic targets, UCL Wellcome Trust PhD Programme for Clinicians
OpenAlex ID: W4327681881
